Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lee

Showing results (311-320 of 337) with videos related to

Pageof 34
Sort By:
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Endoscopy International Open|January 26, 2026
Endoscopic ultrasound-guided radiofrequency ablation for large branch-duct intraductal papillary mucinous neoplasms: Safety and efficacy trialSomashekar G Krishna, Erica Park, Jennifer Rath, et al.
Gastrointestinal Endoscopy|November 18, 2024
Interobserver agreement in dysplasia grading of intraductal papillary mucinous neoplasms: performance of Kyoto guidelines and optimization of endomicroscopy biomarkers through pathology reclassificationMatthew Leupold, Wei Chen, Ashwini K Esnakula, et al.
NAM Perspectives|September 30, 2022
The Promise of Digital Health: Then, Now, and the FutureAmy Abernethy, Laura Adams, Meredith Barrett, et al.
Nature Medicine|February 22, 2024
To do no harm - and the most good - with AI in health careCarey Beth Goldberg, Laura Adams, David Blumenthal, et al.
The Lancet. Haematology|November 20, 2022
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trialAlex F Herrera, Lu Chen, Yago Nieto, et al.
JCI Insight|July 24, 2023
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Hormone Research in Paediatrics|February 4, 2024
Multi-Stakeholder Opinion Statement on the Care of Individuals Born with Differences of Sex Development: Common Ground and Opportunities for ImprovementMartine Cools, Earl Y Cheng, Joanne Hall, et al.
JCI Insight|January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Pageof 34

Showing results (311-320 of 337) with videos related to

Sort By:
Pageof 34
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Endoscopy International Open|January 26, 2026
Endoscopic ultrasound-guided radiofrequency ablation for large branch-duct intraductal papillary mucinous neoplasms: Safety and efficacy trialSomashekar G Krishna, Erica Park, Jennifer Rath, et al.
Gastrointestinal Endoscopy|November 18, 2024
Interobserver agreement in dysplasia grading of intraductal papillary mucinous neoplasms: performance of Kyoto guidelines and optimization of endomicroscopy biomarkers through pathology reclassificationMatthew Leupold, Wei Chen, Ashwini K Esnakula, et al.
NAM Perspectives|September 30, 2022
The Promise of Digital Health: Then, Now, and the FutureAmy Abernethy, Laura Adams, Meredith Barrett, et al.
Nature Medicine|February 22, 2024
To do no harm - and the most good - with AI in health careCarey Beth Goldberg, Laura Adams, David Blumenthal, et al.
The Lancet. Haematology|November 20, 2022
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trialAlex F Herrera, Lu Chen, Yago Nieto, et al.
JCI Insight|July 24, 2023
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Hormone Research in Paediatrics|February 4, 2024
Multi-Stakeholder Opinion Statement on the Care of Individuals Born with Differences of Sex Development: Common Ground and Opportunities for ImprovementMartine Cools, Earl Y Cheng, Joanne Hall, et al.
JCI Insight|January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Pageof 34